Carmen Pilar Simeón i Aznar Institutions of which they are part Main researcher Systemic Diseases Vall Hebron Institut de Recerca Email Carmen Pilar Simeón i Aznar Email Institutions of which they are part Main researcher Systemic Diseases Vall Hebron Institut de Recerca
Research lines Spanish Registry of Scleroderma patients (Systemic Autoimmune Diseases Group, Spanish Internal Medicine Association). This multicentric study includes 14 hospitals with a cohort of 916 scleroderma patients. Its main goal consists in determining both the prognosis factors and the survival of these patients. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Significance of Capillaroscopy in Raynaud's phenomenon and scleroderma. We want to describe the capillaroscopy alterations observed in patients with Raynaud's phenomenon and scleroderma. Our main objective is to establish the different patterns that may be related to visceral involvement and to the prognosis in the early stages of the disease. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Protein expression of small collagenase 3 and leucine-rich proteoglycans in cutaneous tissue of patients with diffuse scleroderma. This study, carried out along with researchers from the Hospital del Mar and from the "Institut Municipal d'Investigació Mèdica", aims at correlating the expression of SLRPs and MMP-13 with the severity of cutaneous involvement, hand dysfunctional capacity, capillaroscopy patterns, and cutaneous ultrasonography of patients affected with diffuse scleroderma in different evolutive stages of the disease. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Evaluation and characterization of cardiac involvement in patients with Systemic Sclerosis. Cardiac involvement is one of the most serious internal organ involvements and the leading cause of death in SSc patients. The prevalence is 14% by clinical observation and even higher by autopsy Many SSc patients with cardiac involvement are asymptomatic or underdiagnosed. The condition may progress silently to overt clinical manifestations, including systolic and/or diastolic dysfunction, myocardial ischaemia, myocardial hypertrophy, heart failure, pericardial effusion and arrhythmias. Early detection of cardiac abnormalities is therefore very important. We evaluate cardiac involvement by echocardiography, MR, SPECT, and coronary CT. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Pagination Current page 1 Page 2 Next page › Last page » Projects EUSTAR PROJECT 2023 IP: Carmen Pilar Simeón i Aznar Collaborators: - Funding agency: European Scleroderma Trials and Research group Funding: 20000 Reference: EUSTAR/GRANT/2023/SIMEON Duration: 01/05/2024 Ajuts Grups de Recerca (SGR) 2022 IP: Jaume Alijotas Reig Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Laura Donaire Lancharro, Ariadna Anunciacion Llunell Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00048 Duration: 01/01/2022 - 30/06/2025 Estudio de expresión de antígenos en tejido tumoral de pacientes con Esclerosis Sistémica. IP: Alfredo Guillen Del Castillo Collaborators: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla, Maria Roca Herrera, Janire Perurena Prieto, Irene Sansano Valero Funding agency: Instituto de Salud Carlos III Funding: 75020 Reference: PI22/01804 Duration: 01/01/2023 - 31/12/2025 Design of an integrative patients stratification approach for the systemic sclerosis management IP: Carmen Pilar Simeón i Aznar Collaborators: - Funding agency: Fundació La Marató de TV3 Funding: 72250 Reference: 202022-30-31-32-33 Duration: 10/05/2021 - 31/12/2024 Pagination Current page 1 Page 2 Page 3 Next page › Last page »
